Sirtex is a global life-sciences company that markets SIR-Spheres® Y-90 resin microspheres, a targeted radiation therapy for patients with inoperable primary or secondary (metastatic) liver tumours. Sirtex has supplied over 86,000 doses of SIR-Spheres Y-90 resin microspheres to 1,160 centres in over 40 countries worldwide. Sirtex (SRX) is listed on the Australian Securities Exchange.

Our significant investments in people, research, product development, marketing, clinical studies and other sales growth initiatives has created a foundation for a global business that will continue to create value over the coming years.

The vision of Sirtex is that cancer will no longer be a terminal disease …but a disease that patients can successfully live with.

The global Sirtex team over the past few years has grown significantly and we now have over 266 employees located in 20 countries.

The Global Head Office of Sirtex is in Sydney, Australia, the Americas Regional Headquarter is located in Boston, USA and the European, Middle East, African (EMEA) Regional Headquarter is located in Bonn, Germany. 

About Sirtex

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.